Century Therapeutics, Inc. (IPSC): Nasdaq/NYSE listing notice — Century Therapeutics gets Nasdaq extension to Feb 2026 for bid price compliance; transfers to Capital Market

Century Therapeutics, Inc.

Received 180-day extension until Feb 23, 2026 to meet $1.00 minimum bid price rule after Aug 26 initial deadline.
Nasdaq approved transfer from Global Select to Capital Market effective Aug 27, 2025; stock continues under IPSC.
Company will consider a reverse stock split to cure the bid price deficiency.
No assurance of regaining compliance; delisting remains possible if price fails to close at $1.00 for 10 consecutive days.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Century Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

August 27, 2025, Nasdaq notified the Company that it had granted the Company an additional 180 calendar day period, or until February 23, 2026 (the “ Extended Compliance Date ”), to regain compliance with the Bid Price Rule. Nasdaq’s determination was based on, among other things, (1) the Company meeting the continued listing requirement for market value of publicly held shares and all other initial listing requirements for The Nasdaq Capital Market, with the exception of the Bid Price Rule, and (2) the Company’s written notice of its intention to cure the deficiency by effecting a reverse sto

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Century Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-085658

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.